Accuronix Therapeutics is a leader in discovering and developing a new class of drugs that work by selectively targeting the σ-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads.

NleB1 is an important virulence factor expressed by multiple bacteria including enterohemorrhagic Escherichia coli (EHEC), enteropathogenic E. coli (EPEC), and Salmonella enterica.

Sphingosine 1-phospate metabolizing enzymes are involved in modulating cellular responses to a variety of viruses in human and veterinary applications. 

Nearly 40 percent of active pharmaceutical ingredients under development are poorly soluble in aqueous media leading to low bioavailability and erratic absorption. In an attempt to solve this issue, researchers began to develop nanocrystals of these insoluble drugs.

Researchers at Kansas State University have identified two synthetic compounds that show
strong activity against various species of C. albicans including C. krusei, C. glabarata and azole
resistant clinical isolates of C. albicans, Aspergillus nidulans, Cryptococcus spp and
dermatophytes.

Each year in the United State alone, $17 billion is spent on healthcare for heart failure. Worldwide, there are 26 million people living with heart failure and 50% of these people will die within 5 years of diagnosis.

Titanium dioxide nanoparticles are doped or co-doped with elements such as nitrogen to produce novel multifunctional nanoparticles that are capable of addressing the current need for biomaterials that have non-leaching and long-lasting antibacterial properties.

A biocompatible and biodegradable delivery vehicle decorated with anti-CD38 monoclonal antibodies for the treatment of MM.

A proprietary high-throughput screening method to identify and characterize in-cell based assays compounds that inhibit FATP2 mediated fatty acid uptake.

Combination of Proton Pump Inhibitors (PPIs) Omeprazole and Lansoprazole in a buffered composition for 24-hour gastric pH control to treat a variety of acid-related disorders such as Barrett’s Esophagus, Gastroesophageal Reflux Disease, and others. 

This novel receptor composition redirects the cytotoxicity of T-lymphocytes towards the FLT3 receptor expressing acute myeloid leukemia (AML) cells by expressing a chimeric antigen receptor (CAR) with FLT3 ligand (FL) at the extracellular antigen-binding domain.

The United States has about 220,000 cases a year of acute respiratory distress syndrome, or ARDS, which deactivates the naturally occurring lung surfactant in patients. That causes a decreased ability to inflate the tiny air sacs in lungs called alveoli. When inadequately inflated, the alveoli cannot totally oxygenate a patient’s blood stream, which can lead to organ failure and other health problems.

Metformin, a naturally-occurring biguanide, is an FDA-approved high-safety profile diabetes drug that has been used extensively for decades.

Researchers at the University of Kentucky have demonstrated that elevated fasting levels of neurotensin could be a potential target for treating obesity and insulin resistance. Additionally, high levels of neurotensin in non-obese patients doubles the risk of the development of obesity later in life, thus presenting a potential protective effect for neurotensin as a therapeutic target.

InnoBioPharma has developed several novel drug candidates (two in pre-clinical trials) that are particularly effective against aggressive cancers that lack effective drug therapy.

A molecule capable of specifically inhibiting the NF-κB pathway, a key target involved in a variety of cancers and other diseases.

OU researchers have identified a novel, selective PPAR-alpha agonist with potential therapeutic effect on diabetic retinopathy and age-related macular degeneration. 

An effective method of treatment for chronic and inflammatory pain by inhibiting selective adenylyl cyclases, especially adenylyl cyclase 1. Compounds may also prevent and/or reduce opioid dependence.

Fungal infections are known to develop resistance to commonly used azoles that are in use in the clinic today.  There remains a need for an effective and safe alternative to treating drug-resistant fungal strains in both humans and plants, and this technology addresses this critical point as an efficacious azole-based therapy which can treat drug resistant fungal infections.

A substrate mediated delivery system for highly controlled local and sustained release of any hydrophobic or hydrophilic cargo.

Cancer treatments with minimal adverse events and improved efficacy are what every pharmaceutical/biotech company strives for in their R&D pipeline.

Therapeutic peptides to combat excessive inflammation and tissue damage in response to ischemia/reperfusion (IR).

Fragment-based drug discovery is a popular method used to design molecules that bind to protein targets. In this method, many small compounds are screened for their binding to a target protein.

Cell-specific non-toxic reagent for the treatment of hematological and other cancers. Data using micelles composed of peptide amphiphiles targeted using aptamers demonstrate efficacy against a wide range of human and canine cancers, as well as low toxicity in vivo, and 2-3x longer median survival.  Patents issued and pending.

A therapeutic vaccine for patients with recurrent prostate cancer that effectively destroys expressing tumor cells while leaving normal cells unharmed.

University of Nebraska-Lincoln researchers are developing a novel protein based delivery technology that targets sensory neurons to stop pain signals at the source to avoid systemic toxicity and addiction potential.

In humans, there are two nearly identical copies of the Survival Motor Neuron (SMN) gene, SMN1 and SMN2.  Loss of SMN1 in conjunction with skipping of SMN2 exon 7 in pre-mRNA splicing—which results in a truncated, unstable SMN—leads to spinal muscular atrophy. 

Orion BioScience is a preclinical stage biotechnology company focused on developing innovative therapies to intercept disease and prevent development of symptoms in autoimmune conditions such as type-1 diabetes and neuromyelitis optica.

Viosera targets under-served deadly infectious disease markets. We use existing FDA-approved and off-patent drugs and combine them in ways that enhance their effectiveness against the deadliest infections.

Antibody-drug conjugates are an increasingly important class of cancer therapeutics.

Viewpoint Molecular Targeting, Inc. develops radiopharmaceuticals for cancer therapy and diagnostic agents.

Combination treatment of Ig-GAD2 and stem cells to cure Type I Diabetes (TID).  Data demonstrate a functional cure in a mouse model for TID through restoration of immune tolerance coupled with regeneration of endothelial cells in the pancreatic islets. Patents issued and pending.

The TR3 molecule is a unique bioactive trimer of TNF superfamily TRAIL (TNF-related apoptosis-inducing ligand, designated TR3) that has been developed with a highly targeted affinity for cancer cells. This unique fused TR3 overcomes historical challenges faced by TRAIL therapies.